Atropine and Spectacle lens Combination Treatment (ASPECT): 12-month results of a randomised controlled trial for myopia control using a combination of Defocus Incorporated Multiple Segments (DIMS) lenses and 0.025% atropine

Further Publications

3-year results of 0.01% and 0.1% loading dose atropine treatment including washout in Danish children with myopia: a placebo-controlled, randomised clinical trial

Br J Ophthalmol

Hansen N, Hvid-Hansen A, Møller F, Bek T, Larsen D, Jacobsen N, Kessel L

doi: 10.1136/bjo-2024-326918

Lenses

Effect of daily disposable Defocus Incorporated Soft Contact lens on myopia control: a 1-year multicentre randomised controlled trial

Br J Ophthalmol

Liu L, Wang J, Tse DY, Zuo B, Song D, Du B, Chen Z, To CH, Chun RKM, Jiang J, Wei R

doi: 10.1136/bjo-2025-327471

Lenses

Efficacy of spectacle lenses for myopia control: a meta-analysis of randomised controlled trials

Br J Ophthalmol

D'Andrea L, Rinaldi M, Piscopo R, Iorio F, La Padula S, Maqsood S, Elalfy M, Melenzane A, Confalonieri F, Ozkan O, Utine CA, Costagliola C

doi: 10.1136/bjo-2025-327629

Further Publications

Diversified Segmental Defocus Optimization Lenses With and Without Atropine for Myopia Prevention: A Randomized Clinical Trial

JAMA Ophthalmol

Lu Y, Yang X, Zhou J, Chen S, Li X, Deng Y, Zhang Y, Li Y, Wang K

doi: 10.1001/jamaophthalmol.2025.2072

Blindness and Vision Impairment

Orthokeratology, 0.04% Atropine, and 0.01% Atropine for Myopia Control: A Randomized Clinical Trial

JAMA Ophthalmol

Xu H, Chen M, Ye L, Shu Q, Peng Y, Liang X, Yu T, Ji Y, Li S, Shen Q, He J, Li L, Zhu J, Xu X

doi: 10.1001/jamaophthalmol.2025.2321

RECOMMENDED

Further Publications

Efficacy and Safety of Different Atropine Regimens for the Treatment of Myopia in Children: Three-Year Results of the MOSAIC Randomized Clinical Trial

★ 3 Recommended by Prof. Dr Ke Yao, Faculty Member

JAMA Ophthalmol

Loughman J, Lingham G, Nkansah EK, Kobia-Acquah E, Flitcroft DI

doi: 10.1001/jamaophthalmol.2024.5703

Macular DiseasesRetinal Diseases

Impact of retinal thickness fluctuations with ranibizumab versus aflibercept in neovascular age-related macular degeneration (SALT): 12-month results from a multicentre, randomised, phase IV trial

Br J Ophthalmol

Agostini HT, Silva R, Holz FG, Larsen M, Altay L, Souied EH, Quiering C, Rose U, Liakopoulos S, SALT study group

doi: 10.1136/bjo-2024-326526

Macular Diseases

Comparison of treatment routine using aflibercept: Strict vs. relaxed retreatment regimen (TOLERANT study)-A non-inferiority, randomized controlled trial

Acta Ophthalmol

Jaggi D, Berger LE, Zweifel S, Becker MD, Michels S, Stalder O, Lincke JB, Habra O, Wolf S, Zinkernagel MS

doi: 10.1111/aos.17514

Further Publications

Efficacy of cylindrical annular refractive elements (CARE) spectacle lenses in slowing myopia progression over 2 years

Am J Ophthalmol

Chen X, Wu M, Yu C, Ohlendorf A, Li W, Liu N, Yang Y, Li L, Sankaridurg P

doi: 10.1016/j.ajo.2025.06.017

Related content

3-year results of 0.01% and 0.1% loading dose atropine treatment including washout in Danish children with myopia: a placebo-controlled, randomised clinical trial

Effect of daily disposable Defocus Incorporated Soft Contact lens on myopia control: a 1-year multicentre randomised controlled trial

Efficacy of spectacle lenses for myopia control: a meta-analysis of randomised controlled trials

Diversified Segmental Defocus Optimization Lenses With and Without Atropine for Myopia Prevention: A Randomized Clinical Trial

Orthokeratology, 0.04% Atropine, and 0.01% Atropine for Myopia Control: A Randomized Clinical Trial

Efficacy and Safety of Different Atropine Regimens for the Treatment of Myopia in Children: Three-Year Results of the MOSAIC Randomized Clinical Trial

Impact of retinal thickness fluctuations with ranibizumab versus aflibercept in neovascular age-related macular degeneration (SALT): 12-month results from a multicentre, randomised, phase IV trial

Comparison of treatment routine using aflibercept: Strict vs. relaxed retreatment regimen (TOLERANT study)-A non-inferiority, randomized controlled trial

Efficacy of cylindrical annular refractive elements (CARE) spectacle lenses in slowing myopia progression over 2 years